Alzheimer's disease (AD) is a neurodegenerative disorder, most cases of which lack a clear
causative event. This has made the disease difficult to characterize and, thus, diagnose …

As the median age of the population increases, the number of individuals with Alzheimer's
disease (AD) and the associated socio-economic burden are predicted to worsen. While …

Amyloid precursor protein (APP) gives rise to the amyloid-β peptide and thus has a key role
in the pathogenesis of Alzheimer disease. By contrast, the physiological functions of APP …

The spread of neurodegeneration through the human brain network is reported as
underlying the progression of neurodegenerative disorders. However, the exact …

Cleavage of the amyloid precursor protein (APP) by α-secretase generates an extracellularly
released fragment termed secreted APP-alpha (APPsα). Not only is this process of interest …

We have previously reported long-term changes in the brains of non-concussed varsity
rugby players using magnetic resonance spectroscopy (MRS), diffusion tensor imaging (DTI) …

Rivastigmine (or Exelon) is a cholinesterase inhibitor, currently used as a symptomatic
treatment for mild-to-moderate Alzheimer's disease (AD). Amyloid-β peptide (Aβ) generated …

The field of Alzheimer's disease (AD) research critically lacks an all-inclusive etiology theory
that would integrate existing hypotheses and explain the heterogeneity of disease trajectory …

Amyloid beta peptide is an important biomarker in Alzheimer's disease, with the
amyloidogenic hypothesis as one of the central hypotheses trying to explain this type of …

ADAM10 (A Disintegrin and Metalloproteinase 10) has been identified as the major
physiological alpha-secretase in neurons, responsible for cleaving APP in a non …